Overview


According to FutureWise analysis, the point of care diagnostics market in 2025 is US$51.19 billion, and is expected to reach US$88.75 billion by 2033 at a CAGR of 7.12%. The point-of-care diagnostics market is undergoing a significant transformation due to the increasing global demand for quicker and more accessible healthcare solutions. Recent innovations in portable testing devices, real-time disease detection, and AI-integrated diagnostics are enhancing patient care in both remote and clinical settings. This rapid expansion is indicative of a broader trend towards decentralized, efficient, and patient-centered healthcare delivery, aimed at improving outcomes and accessibility for patients.

Key growth drivers: Increasing demand for rapid molecular tests, multiplex respiratory and STI panels, digital integration with electronic medical records, and expansion into outpatient and low-resource settings.

Challenges: Post-COVID adjustments, increased regulatory scrutiny (particularly for over-the-counter and home molecular tests), and consolidation among vendors.

Molecular POC growth – Fast and accurate NAAT platforms are being increasingly utilized at the bedside.

Digital & connected diagnostics – Integrating with mobile apps and electronic medical records (EMRs) is a crucial differentiating factor.

Point-of-care diagnostics (POCT) refers to the practice of conducting medical diagnostic tests and analyses at or near the location where a patient is receiving care, whether it's at the bedside, in a clinic, at a community health center, or even in a non-traditional healthcare setting, such as a pharmacy. This approach eliminates the need for samples to be transported to centralized laboratories, reducing the time between sample collection and result availability. With its quick results and versatility, POCT has found applications in diverse healthcare settings, from hospitals and clinics to remote areas and community centers. The accessibility and cost-efficiency of point-of-care testing make it a powerful tool, particularly in resource-limited settings, where timely diagnosis can be challenging. However, ensuring accurate results, proper training of healthcare staff, and careful consideration of costs remain essential factors in realizing the full potential of this approach. Overall, point-of-care diagnostics represent a significant advancement in healthcare delivery, empowering patients and healthcare professionals with immediate, actionable information for improved patient outcomes.

FutureWise Market Research has published a report that provides an insightful analysis of Point of Care Diagnostics market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry.

According to the analysis conducted by FutureWise research analysts, the Point of Care Diagnostics market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Abbott
  • AccuBioTech
  • BioMérieux SA
  • Bio-Rad Laboratories
  • Becton Dickinson, and Company
  • Chembio Diagnostics
  • Danaher
  • EKF Diagnostics
  • F. Hoffmann-La Roche
  • Werfen (Instrumentation Laboratory)
  • Johnson & Johnson
  • Nova
  • PTS Diagnostics
  • Sekisui Diagnostic
  • Siemens Healthineers
  • Sinocare Inc.
  • Sysmex Corporation
  • Trinity Biotech
  • Trividia Health Inc.,0
  • QIAGEN
  • Quidel

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in the Point of Care Diagnostics Market:

Abbott

  • In April 2024, Abbott's i-STAT TBI cartridge, designed for detecting traumatic brain injuries, received FDA clearance for the use of direct whole blood, enhancing rapid on-site neurological assessment capabilities.
  • The company maintains its leadership in the POC market with approximately 23% market share projected for 2024, offering a robust portfolio that includes glucose monitoring, ID NOW molecular assays, and CRP testing.
  • The company is expanding its ID NOW rapid molecular platform, which provides results in just 13 minutes.
  • The company has enhanced its portfolios for respiratory and strep testing.

Siemens Healthineers

  • Siemens has integrated AI analytics into its POC devices, such as handheld troponin and blood gas analyzers, enhancing diagnostic accuracy and making them compatible with smartphones and the cloud.
  • The RAPIDPoint, Epoc, and DCA product lines are expanding in hospitals and emergency services.

Becton Dickinson and Company

  • In May 2023, BD obtained clearance for its AI-driven Kiestra MRSA imaging tool. This innovative technology is designed to alleviate the workload of laboratories by streamlining the identification of bacterial pathogens, with a specific focus on MRSA (Methicillin-resistant Staphylococcus aureus).
  • The company has made significant acquisitions, including a $4.2 billion deal in Critical Care that enhances its real-time monitors.

 

  • In November 2022, LumiraDx Healthcare launched a highly sensitive C-Reactive Protein (CRP) point-of-care test in India. This test helps clinicians quickly determine if symptoms are arisisng from bacterial infection, reducing unnecessary antibiotic prescribing that contributes to antimicrobial resistance (AMR). This innovation enables more targeted treatment decisions and supports efforts to combat the growing issue of antibiotic resistance.
  • In October 2022, Genes2Me Pvt. Ltd introduced the Rapi-Q Point of Care RT PCR solution, designed for detecting human papillomavirus (HPV) and tuberculosis. This device offers user-friendly operation and provides rapid results in under 45 minutes. With a CE-IVD marking, this point-of-care solution demonstrates excellent performance, notable sensitivity, and consistent detection capabilities.

By Product

  • Glucose Monitoring Products
    • Strips
    • Meters
    • Lancets and Lancing Platform
  • Cardiometabolic Testing Products
    • Cardia Marker Testing Products
    • Blood Gas/Electrolytes Testing Products
    • HBA1C Testing Products
  • Infectious Disease Testing Products
    • HIV testing Products
    • Hepatitis C Testing Products
    • Sexually Transmitted Disease (STD) Testing Products
    • Healthcare-Associated Infection (HAI) Testing Products
    • Respiratory Infection Testing Products
    • Tropical Disease Testing Products
    • Other Infectious Disease testing Products
  • Coagulation Testing Products
    • PT/INR Testing Products
    • Activated Clotting Time (ACT/APTT) Testing Products
  • Pregnancy and Fertility Testing Products
    • Tumour/Cancer Marker Testing Products
    • Urinalysis Testing Products
    • Cholesterol Testing Products
    • Hematology testing Products
    • Drug-of-Abuse Testing Products
    • Fecal Occult Testing Products
    • Other POC Products

By Platform

  • Agglutination Assays
  • Immunoassays
  • Biosensors
  • Dipsticks
  • Lateral Flow Assays
  • Microfluidics
  • Molecular Diagnostics
  • Solid Phase

By Mode

  • Prescription-Based Testing
  • OTC Testing

By End User

  • Home Care/ Self Testing
  • Physician Offices and Outpatient Centers
  • Hospitals
  • Research Laboratories
  • Other End Users

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa

Here’s a regional view of where the most progress is happening

  • North America – Most advanced; leads in molecular POC, digital integration, and home/OTC testing.

  • Europe – Strong innovation; focus on chronic disease and infectious POC testing.

  • Asia-Pacific – Fastest growth; driven by large populations, rural healthcare needs, and manufacturing expansion.

The market is segmented by region into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest market of 40.9% in 2022. The region is at the point of significant growth, propelled by the strong presence of influential market players and a notable increase in both chronic and infectious diseases. Recent instances of company acquisitions and new product introductions are acting as driving forces behind the expansion of the analyzed market. For instance, the acquisition was carried out by Heska Corporation, a well-established US-based company renowned for its advanced veterinary diagnostics and specialty solutions. This strategic maneuver, which took place in January 2023, involved the acquisition of MBio Diagnostics, Inc. This move is a testament to the power of strategic acquisitions in propelling market growth within the region.

Furthermore, another milestone was reached in May 2022, as the NOWDiagnostic's ADEXUSDx hCG Test received clearance from the USFDA. Designed for qualitative human chorionic gonadotropin (hCG) detection in human blood, plasma, or serum, this immunoassay test serves as an early pregnancy detection tool for healthcare professionals in various clinical settings. The regulatory endorsement of novel POC diagnostics, such as this, underscores its impact in contributing to the expansion of the studied market within the region.

Additionally, the Infectious disease testing products market registered a 40.8% market share by product type in 2022. The landscape of infectious disease testing has transformed from centralized setups to decentralized Point-of-Care (POC) testing, leading to enhanced patient care outcomes. This shift has been driven by a growing need for rapid testing solutions, prompting industry leaders to bring POC innovations to decentralized areas. An illustrative example of this trend is evident in Abbott's pioneering effort with ID NOW, the fastest molecular POC test globally. This ground-breaking test delivers COVID-19 results within a mere 13 minutes, making it a valuable asset in a range of decentralized healthcare environments, including physicians' offices and urgent care clinics. Also, by platform, lateral flow assay registered a 29.6% market share in 2022. Also, by mode, prescription-based testing, and by end-user, hospitals registered 59.5% and 35.4% market share, respectively.

Driver For Point of Care Diagnostics Market:

Sedentary lifestyles, lack of exercise, and poor eating habits have led to a rise in conditions like obesity, diabetes, and hypertension. Also, aging demographics play a pivotal role in the rise of chronic diseases. For instance, as projected by the WHO, the global population above 60 years is set to reach remarkable proportions by 2030 and beyond, with the 60+ age group doubling to 1.4 billion by 2030 and tripling to 2.1 billion by 2050. This growing segment necessitates consistent monitoring and swift access to diagnostic tests, where POC diagnostics prove to be an indispensable tool for effective health management. The demand for POC diagnostics is propelled by the imperative of early detection and prevention of chronic illnesses. Early diagnosis holds the key to improved treatment outcomes and a reduced burden on both individuals and healthcare systems. POC diagnostic devices excel in their ability to deliver rapid and efficient test results, enabling timely interventions and proactive disease management. This capacity to detect ailments at their nascent stages greatly contributes to improved patient outcomes and concurrently aids in curtailing the escalating healthcare costs associated with advanced disease progression. Due to POC various application and advantages the market is expected to grow rapidly during forecast period.

Restrain For Point of Care Diagnostics Market:

The regulatory approval process is expected to constrain the POC diagnostic market. Securing clearance involves multiple review stages, necessitating comprehensive technical documents, clinical reports, and quality data submissions. Regulatory bodies meticulously assess these documents to gauge device safety, performance, and intended usage. Regulatory bodies like the FDA in the US and EMA in Europe maintain strict standards to ensure diagnostic device quality, efficacy, and safety. While crucial for patient safety, these regulations can challenge point-of-care (POC) diagnostic companies. Companies aiming for regulatory approval for POC diagnostic devices must furnish substantial evidence of their product's safety and effectiveness, involving rigorous clinical trials and analytical assessments. This entails extensive data collection and analysis, consuming time and resources. Complying with such requirements demands significant R&D investment and regulatory expertise, which is expected to limit the market growth.

Opportunities For Point of Care Diagnostics Market:

Home-based and self-testing solutions have emerged as a growing trend, allowing individuals to conduct diagnostic tests in their own homes without the involvement of healthcare professionals or traditional laboratories. This shift presents a significant opportunity for point-of-care (POC) diagnostic companies to cater to this expanding market. Modern patients seek greater control over their healthcare, and home-based testing aligns with this inclination. This approach offers convenience by eliminating the need for time-consuming healthcare facility visits, reducing wait times, and enabling more frequent monitoring. POC diagnostic devices empower individuals to perform self-tests, receive immediate results, and take proactive steps based on those outcomes. The demand for home-based and self-testing devices is also fueled by the prevalence of chronic diseases requiring continuous monitoring. Conditions like diabetes, hypertension, and cardiovascular ailments necessitate regular vital signs and biomarkers assessment. Home-based testing empowers individuals to closely track their health status and make timely adjustments to treatment plans, often in consultation with healthcare providers. POC diagnostic devices provide reliable results, facilitating effective health parameter monitoring. This experience has increased public awareness and acceptance of home-based testing for other diseases, allowing POC diagnostic companies to expand their offerings in this target market.

Trend For Point of Care Diagnostics Market:

Integrating Point-of-Care Diagnostic (POCD) devices with telemedicine platforms is a growing trend with numerous healthcare advantages. This combination enables remote patient monitoring, granting healthcare professionals real-time data for timely interventions. It also extends specialized care to remote areas and enhances patient convenience by eliminating the need for routine visits. The seamless data exchange supports better decision-making and patient engagement, promoting active involvement in health management. This synergy between POCD devices and telemedicine highlights the potential for technology to revolutionize healthcare delivery. Thus, the growing trend of telemedicine is expected to enhance the growth of the target market.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • FutureWise research report will help you understand the growth prospects, key trends, and data points affecting the market's growth.
  • A detailed review of strategies being opted by the players in this market, and a thorough market share registered by the key companies globally as well as on a regional basis.

  • To provide with an exhaustive analysis on the of Point of Care Diagnostics Market By Product, By Platform, By Mode, By End-user and By Region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections which are represented in the format of data-sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches.

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction

    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders

  • 2.   Research Methodology

    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data From Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study

  • 3.  Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Point of Care Diagnostics Market Variables, Trends and Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards And Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Point of Care Diagnostics Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Point of Care Diagnostics MarketAnalysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Point of Care Diagnostics Market, By Product Historical Analysis and Forecast 2025-2033 (USD Million)

    •   1. Glucose Monitoring Products
         1.1. Strips
         1.2. Meters
         1.3. Lancets and Lancing Platform
        2. Cardiometabolic Testing Products
         2.1. Cardia Marker Testing Products
         2.2. Blood Gas/ Electrolytes Testing Products
         2.3. HBA1C Testing Products
        3. Infectious Disease Testing Products
         3.1. Influenza Testing Products
         3.2. HIV Testing Products
         3.3. Hepatitis C Testing Products
         3.4. Sexually Transmitted Disease Testing Products
         3.5. Healthcare Associated Infection Testing Products
         3.6. Respiratory Infection Testing Products
         3.7. Tropical Disease Testing Products
         3.8. Other Infectious Disease Testing Products
        4. Coagulation Testing Products
         4.1. PT/INR Testing Products
         4.2. Activated Clotting Time Testing Products
        5. Pregnancy and Fertility Testing Products
         5.1. Tumor/ Cancer Marker Testing Products
         5.2. Urinalysis Testing Products
         5.3. Cholesterol Testing Products
         5.4. Hematology Testing Products
         5.5. Drug-of-Abuse Testing Products
         5.6. Fecal Occult Testing Products
         5.7. Other POC Testing Products

  • 8.   Point of Care Diagnostics Market, By Platform Historical Analysis and Forecast 2025-2033 (USD Million)

    •   1. Agglutination Assays
        2. Immunoassays
        3. Biosensors
        4. Dipsticks
        5. Lateral Flow Assays
        6. Microfluidics
        7. Molecular Diagnostics
        8. Solid Phase

  • 9.   Point of Care Diagnostics Market, By Mode Historical Analysis and Forecast 2025-2033 (USD Million)

    •   1. Prescription-Based Testing
        2. OTC Testing

  • 10.   Point of Care Diagnostics Market, By End User Historical Analysis and Forecast 2025-2033 (USD Million)

    •   1. Home Care/ Self Testing
        2. Physician Offices and Outpatient Centers
        3. Hospitals
        4. Research Laboratories
        5. Other End Users

  • 11.   North America Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2025-2033

  • 12.   Latin America Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)

    •   1. Introduction
        2. Regional Market Trends
        3. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         3.1. Brazil
         3.2. Venezuela
         3.3. Argentina
         3.4. Rest of Latin America
        4. Market Size (USD Million) Forecast for Latin America 2025-2033

  • 13.   Europe Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Switzerland
         2.9.Rest of Western Europe
        4. Market Size (USD Million) Forecast for Europe 2025-2033

  • 14.   Asia Pacific Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         2.1. Japan
         2.2. China
         2.3. Singapore
         2.4. India
         2.5. Australia and New Zealand
         2.6. ASEAN
         2.7. South Korea
         2.8. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2025-2033

  • 15.   Middle East and Africa Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2025-2033

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts)

    •   1. ABBOTT  
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. ACCUBIOTECH
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. BIOMERIEUX SA
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. BIO RAD LABORATORIES
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. BECTON DICKINSON AND CO.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. CHEMBIO DIAGNOSTICS
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. DANAHER
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. EKF DIAGNOSTICS
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. F-HOFFMANN LA ROCHE
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Werfen (INSTRUMENTATION LABORATORY)
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. JOHNSON & JOHNSON
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. NOVA
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. PTS DIAGNOSTICS
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. SEKISUI DIAGNOSTICS
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. SEIMENS HEALTHINEERS
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. Sinocare Inc.
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. Sysmex Corporation
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview
        18. Trinity Biotech
         18.1. Company Overview
         18.2. Product Portfolio
         18.3. SWOT Analysis
         18.4. Financial Overview
         18.5. Strategic Overview
        19. Trividia Health Inc.
         19.1. Company Overview
         19.2. Product Portfolio
         19.3. SWOT Analysis
         19.4. Financial Overview
         19.5. Strategic Overview
        20. QIAGEN
         20.1. Company Overview
         20.2. Product Portfolio
         20.3. SWOT Analysis
         20.4. Financial Overview
         20.5. Strategic Overview
        21. Quidel
         21.1. Company Overview
         21.2. Product Portfolio
         21.3. SWOT Analysis
         21.4. Financial Overview
         21.5. Strategic Overview

  • 18.  Pre and Post COVID-19 Impact

    •       1. Positive influence on the healthcare industry
            2. The financial disruption of the manufacturing sector
            3. Impact of COVID-19 on emerging companies
            4. Significant mandates in the healthcare regulations initiated
                by administrations
            5. The overall economic slowdown of the developing and developed nations

  • 19.   FutureWise SME key Takeaway Points for Client

FAQ


Point-of-care (POC) diagnostics are medical tests conducted near patients, providing rapid results outside of traditional laboratory settings. Examples of these tests include blood glucose meters, rapid antigen tests, and molecular testing devices.
  • There is an increasing demand for quick and precise testing.
  • Expansion of molecular and multiplex testing.
  • Integration with digital health platforms and electronic medical records (EMRs).
  • Expanding access to healthcare in outpatient clinics, urgent care facilities, and low-resource settings.
  • Molecular POC – PCR, NAAT, infectious disease testing.
  • Immunoassays & rapid antigen tests – flu, strep, COVID-19, etc.
  • Chronic disease monitoring – glucose, cholesterol, cardiovascular markers.
  • There is increased regulatory oversight, particularly concerning at-home testing.
  • The high cost of molecular point-of-care (POC) devices.
  • Competition and consolidation among suppliers.

Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 113 519 7222
  • US : +1 347 709 4931

Related Market

Point of Care CT Imaging Systems Market

Read More

Pregnancy Point of Care Testing Market

Read More

Point of Care Molecular Diagnostics Market

Read More

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11